Designing new therapeutic options for heart disease

The percutaneous approach

CardioMech is developing a technology designed to treat a clear unmet clinical need – patients with Mitral Valve Regurgitation.

The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail. The 3 available therapy options for these patients (open heart surgery, edge-to-edge repair, and TA chordal repair) are insufficient. Today 4,000,000 patients globally suffer from severe, symptomatic DMR and there are 220,000 new patients each year.

Caution: The CardioMech device is in the early R&D development phase and is NOT approved or cleared by the FDA or any other regulatory body in any region of the world.

Award Winning Technology

CardioMech's Nikolai Hiorth won the Young Investigator Award at the International Society for Medical Innovation and Technology Congress in Shanghai, China, 2014.


General inqueries
CardioMech AS
7030 Trondheim

Nikolai Hiorth

President and CEO
Rick Nehm

Medical Director
Dr. Jacob Bergsland

CardioMech AS © 2018 · All rights reserved